Becton, Dickinson and Company insider Thomas Polen filed to sell up to 4,152 shares of common stock through Morgan Stanley Smith Barney LLC, following an exercise of stock options for cash on 08/13/2026. The planned sale has an aggregate market value of $762,224.16, based on a $272.386800 per-share price, and follows prior Rule 10b5-1 sales of 2,764 shares for $404,524.31 on 06/01/2026.
Becton Dickinson & Co executive Roland Goette, EVP and President, EMEA, reported selling 2,438 shares of Common Stock on August 11, 2026 in an open market or private transaction at $180.84 per share. The shares sold were acquired through the company’s Global Share Investment Program (GSIP). Following this sale, Goette held 14,856 shares directly, with these holdings reflecting the addition of dividends received as part of an equity adjustment tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. He also held 1,779 shares indirectly through a GSIP Trust as of August 3, 2026.
State Street Corporation reported beneficial ownership of 15,014,710 shares of Becton Dickinson & Co. common stock on a Schedule 13G. This represents 5.4% of the outstanding class.
State Street reports no sole voting or dispositive power, but shared voting power over 9,911,498 shares and shared dispositive power over 15,000,067 shares, primarily through affiliated investment management and advisory subsidiaries listed in the filing.
Becton Dickinson director Robert Luther Huffines acquired 189 rights to common stock under the BD Deferred Compensation Plan on 2026-08-06, credited at $165.62 per right. Each right converts into one share of common stock and is distributed after his board service ends or on dates he specifies. After this award, he directly holds 595 rights, including amounts accumulated through dividend investment.
Becton Dickinson director Carrie L. Byington received a grant of 94 rights to Common Stock under the BD Deferred Compensation Plan at a reference price of $165.62 per right. Each right converts one-for-one into Common Stock, bringing her total plan rights to 3,810, including rights added through dividend investment since her last report.
First Eagle Investment Management, LLC reports beneficial ownership of common stock of Becton Dickinson & Co. It is deemed to beneficially own 14,138,027 shares, representing 5.1% of the common stock. First Eagle has sole voting power over 12,845,517 shares and sole dispositive power over 14,138,027 shares.
The shares are held by or at the direction of First Eagle and/or its investment adviser subsidiaries, principally on behalf of investment advisory clients. Clients of First Eagle have the right to receive dividends and proceeds from any sale of these securities.
Becton, Dickinson and Company reported fiscal Q3 2026 revenue from continuing operations of $4,983 million, up 5.4% year over year, with GAAP diluted EPS from continuing operations of $1.64 and adjusted diluted EPS of $3.23, both increasing from the prior-year quarter.
Year-to-date, revenue reached $14,183 million, while net cash provided by continuing operating activities rose 33.3% to $2.1 billion and free cash flow grew 44.6% to $1.7 billion. Results reflect the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business, now treated as discontinued operations.
The company updated its full-year fiscal 2026 outlook, targeting GAAP revenue growth in the low single-digit plus range and revenue growth (FXN) in the low single-digit range, and raised the midpoint of adjusted diluted EPS guidance to $12.62–$12.72 from a prior range of $12.52–$12.72.